Chronic liver diseases, like NASH, with no FDA-approved therapeutic treatment, have benefitted from liver-specific NR targeting like thyroid hormone receptor–β (TR-β).112 TR-β is a nonsteroidal type I NR with extensive effects on metabolism, including body weight and LDL reduction and increased hepatic fatty acid β-oxidation on activation by thyroid hormones.113 Selective modulation of TR-β in the liver by promising drugs such as resmetirom (MGL-3196) and VK2809 (MB07811) have shown to be beneficial in NASH patients participating in phase 2 studies. This evidence concerns the gene TG and metabolic dysfunction-associated steatohepatitis.